As an important link in drug -research and development, Department of Pharmaceutics in the Institute of Materia Medica, Chinese Academy of Medical Sciences was established in the 1980s. After 40 years of development, it has become an academic team with a clear research direction, reasonable personnel echelon, and strong comprehensive scientific research capability. The Department consists of five research groups, including more than 20 formal staff members, 6 professors, 6 associate professors, 5 doctoral supervisors and 3 master’s supervisors. Up to now, more than 80 doctoral and master’s students have graduated, more than 300 academic papers have been published, more than 80 invention patents have been applied for, and more than 50 patents have been authorized.
Based on clinical demand and being problem-oriented, the research teams of the department focus on "innovative design of pharmaceutics" and "R&D of novel drug delivery systems" and have built a domestic leading and international advanced DDS technology platform. The Department of Pharmaceutics has undertaken dozens of major fund projects. With the consolidation of research foundation and the improvement of innovation ability, the department pays more and more attention to the application of basic research and achievement transformation, and has completed R&D of a number of innovative drugs and new preparations, and obtained more than 20 new drug certificates.
Main research interests:
1) Targeted delivery systems based on the regulation pathways of glucose and lipid metabolism;
2) Nanocarrier delivery systems based on tumor targeted therapy;
3) Oral nanomedicines based on immunological targeted therapy;
4) Protein and peptide drug nanocarriers and their mucosal and oral delivery systems;
5) Atomization inhalation and its delivery systems;
6) Functional polymer materials and sustained-controlled release preparations;
7) Molecular taste masking and promotion of oral absorption；
8) Development of novel gene delivery systems；
9) Research on delivery system of biomacromolecule;
10) Combined immunotherapy of tumors ;
11) New dosage forms and preparation products for special populations (such as children, the elderly, women, etc.);
12) Key technologies of high-end excipients;
13) Precise treatment of major diseases.
